Related Experiment Video

Updated: May 24, 2026

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Monoclonal antibodies as cancer therapeutics

Jihene Elloumi1, Karim Jellali, Ikram Jemel

  • 1Centre of Biotechnology of Sfax, PoBox 1177, 3018, Sfax University, Sfax, Tunisia.

Recent Patents on Biotechnology
|March 17, 2012
PubMed

Insights

Monoclonal antibodies (mAbs) show promise in cancer therapy but face challenges. Combining mAbs with other treatments improves their effectiveness, with immunotherapy and related patents offering new avenues for cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Monoclonal antibodies (mAbs) are key in cancer therapy, targeting EGFR, clusters of differentiation, and VEGF.
  • Challenges include side effects, high costs, and resistance, limiting mAb efficacy.
  • Combination therapies with chemotherapy or radiotherapy enhance mAb effectiveness.

Purpose of the Study:

  • To review current immunotherapy strategies in cancer treatment.
  • To explore patents related to monoclonal antibody development for cancer therapy.
  • To highlight advancements and challenges in targeted cancer therapy.

Main Methods:

  • Literature review of established and emerging monoclonal antibodies in cancer treatment.
  • Analysis of clinical trial data on combination therapies involving mAbs.
  • Survey of patent databases for innovations in cancer immunotherapy.

Main Results:

  • EGFR, CD markers, and VEGF are primary mAb targets in solid and blood cancers.
  • Combination therapies significantly improve outcomes compared to mAbs alone.
  • Numerous patents reflect ongoing innovation in mAb-based cancer treatments.

Conclusions:

  • Monoclonal antibodies are vital but require strategic application and combination therapies.
  • Addressing resistance and cost is crucial for broader mAb accessibility.
  • Immunotherapy, supported by patentable innovations, continues to evolve for cancer treatment.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...